drugset / Trial / NCT06793189
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Marginal zone lymphoma (MZL) is a common type of indolent lymphoma that originates from the marginal zone of lymphoid follicles. This study aims to evaluate targeted therapy based on the prognostic risk stratification of MZL-IPI in newly diagnosed MZL cases requiring systemic treatment, and provides a basis for precision treatment of MZL.
Timeline
- Start
- 2025-01-23
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | — |
| Subject | Orelabrutinib | Small molecule | 150 mg | — |